NCT06657781 Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis
| NCT ID | NCT06657781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
| Condition | Bacterial Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 171 participants |
| Start Date | 2022-11-30 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 171 participants in total. It began in 2022-11-30 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
: Sepsis, now defined as life-threatening organ dysfunction due to a dysregulated host response to infection, is an important global health problem representing about a fifth of all global deaths. It can be associated, in some cases, with multiple organ failure and cytokine storm. The main objective of this study is to estimate and to compare the activation rate of the Nucleotide-binding domain Leucine Rich repeat containing Protein 3 (NLRP3) inflammasome in platelets between five groups of patients suffering from bacterial and/or viral sepsis, with different severity levels according to Sequential Organ Failure Assessment (SOFA) score to precise the platelets' implication in this cytokine storm.
Eligibility Criteria
Inclusion Criteria: * For all groups: patients older than 18 years at inclusion and acceptation of participation by the patient, his relative or his legal representative (depending on the situation) * For groups 1, 2, 3 and 5: Patient with a confirmed sepsis (microbiological confirmation) * For group 4 : Patient non infected Exclusion Criteria: * Refusal of participation by the patient, his relative or his legal representative (depending on the situation) * Patients subject to a safeguard measure of justice * Patients younger than 18 years at inclusion
Contact & Investigator
Frédéric MARTINO, Doctor
PRINCIPAL INVESTIGATOR
chu de pointe à pitre
Frequently Asked Questions
Who can join the NCT06657781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bacterial Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06657781 currently recruiting?
Yes, NCT06657781 is actively recruiting participants. Contact the research team at frederic.martino@chu-guadeloupe.fr for enrollment information.
Where is the NCT06657781 trial being conducted?
This trial is being conducted at Les Abymes, Guadeloupe.
Who is sponsoring the NCT06657781 clinical trial?
NCT06657781 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe. The principal investigator is Frédéric MARTINO, Doctor at chu de pointe à pitre. The trial plans to enroll 171 participants.